Merck is leaning on newer drugs and the promise of its pipeline assets as a patent cliff looms for its largest revenue driver, Keytruda.
Yahoo
Skip to navigation
Skip to main content
Skip to right column
Merck Earnings Blow Past Estimates. Why Wall Street Is Looking Past the Numbers. ·
Barrons.com
·
Spencer Platt/Getty Images
